SCHEMBL14596166

SCHEMBL14596166

COc1ccc(S(=O)(=O)N(C)Cc2nc(NCCCN(C)C)c3ccccc3n2)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.54
ACHE P22303 4/20 0.51
RAD52 P43351 3/20 0.49
KDM1A O60341 3/20 0.49
EHMT2 Q96KQ7 3/20 0.49
RCOR1 Q9UKL0 3/20 0.49
POLB P06746 2/20 0.49
RXFP1 Q9HBX9 1/20 0.49
ALDH1A1 P00352 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 1/20 0.47
APP P05067 4/20 0.46
HIF1A Q16665 1/20 0.46
EPAS1 Q99814 1/20 0.46
BCHE P06276 2/20 0.46
PDE4D Q08499 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14596153 0.88 RAD52 (0.55) FLT3RAD52POLBRXFP1ALDH1A1
SCHEMBL14596154 0.88 RAD52 (0.62) FLT3RAD52POLBRXFP1ALDH1A1
SCHEMBL14596163 0.88 FLT3 (0.53) FLT3RAD52POLBRXFP1ALDH1A1
SCHEMBL14596164 0.86 FLT3 (0.56) FLT3ACHERAD52KDM1AEHMT2
SCHEMBL14596171 0.86 FLT3 (0.52) FLT3RAD52POLBRXFP1ALDH1A1
SCHEMBL14596159 0.86 FLT3 (0.57) FLT3RAD52POLBRXFP1ALDH1A1
SCHEMBL14596176 0.86 FLT3 (0.65) FLT3RAD52KDM1APOLBRXFP1
SCHEMBL14596148 0.86 RAD52 (0.60) FLT3RAD52POLBRXFP1ALDH1A1
SCHEMBL14596174 0.86 ALDH1A1 (0.57) FLT3RAD52POLBRXFP1ALDH1A1
SCHEMBL14596147 0.85 RAD52 (0.58) FLT3RAD52POLBRXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment TP53, TP53BP1, ACIN1 FLT3 191/4885ACHE 4163/4885RAD52 954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.